ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Services

IHH Healthcare Bhd.

Company Background

IHH Healthcare runs 37 private hospitals in 10 countries, including China and India. Its facilities have a total of more than 6,000 beds.

Headquartered in Malaysia, the company also sees Singapore and Turkey as its home markets. Its hospitals in these three countries attract affluent patients from across Southeast Asia and the Middle East. The group's Mount Elizabeth and Gleneagles hospitals in Singapore are considered particularly prestigious, thanks to their state-of-the-art medical equipment.

IHH is 44% owned by Khazanah Nasional, an investment arm of the Malaysian government. Khazanah in 2010 defeated a rival bid from India's Fortis Healthcare to take control of Parkway Holdings, a then-listed Singaporean company, which owned hospitals in Malaysia and Singapore. Today, Parkway is a wholly owned IHH subsidiary.

IHH is listed in both Malaysia and Singapore. The group is led by CEO Tan See Leng, who is also a doctor. Tan joined Parkway in 2004 and held various high-ranking positions before the company slid under IHH's umbrella.

Globally, IHH is the second-largest health care operator by market capitalization. Japanese trading house Mitsui & Co. is a major shareholder.

Business Summary

IHH Healthcare Bhd. is an investment holding company, which engages in the provision of healthcare services. It operates through the following segments: Parkway Pantai, PPL Others, CEEMENA, and Others. The Parkway Pantai segment comprises the Parkway Pantai and PLife REIT. The PPL Others segment includes Pantai's hospital in Brunei, and corporate office as well as other investment holding entities within Parkway Pantai. The CEEMENA segment refers to Central and Eastern Europe, Middle East, and North Africa. The company was founded on May 21, 2010 and is headquartered in Kuala Lumpur, Malaysia.

Financial Highlights

Dec 2019 MYRUSD
Gross Profit3,677.11M887.55M
Operating income1,664.98M401.88M
Income before tax968.61M233.79M
Net income463.30M111.82M
Diluted EPS0.050.01
Dividends Per Share0.040.00
Total Assets45,053.28M11,014.12M
Total liabilities19,117.48M4,673.63M
Total equity22,339.53M5,461.32M
Operating cash flow2,683.04M647.61M
Currency in MYRCurrency in USD

Historical Data

 Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019
Revenue 8,455.46M 10,021.88M 11,142.63M 11,520.93M 14,912.48M
Gross Profit 2,327.18M 2,657.91M 2,620.19M 2,902.27M 3,677.11M
Operating income 1,210.55M 1,227.74M 1,068.88M 1,240.72M 1,664.98M
Income before tax 1,203.25M 860.94M 1,162.33M 739.05M 968.61M
Net income 933.90M 612.35M 931.31M 541.84M 463.30M
EBITDA 1,900.05M 2,026.87M 2,046.96M 2,162.14M 3,020.47M
Diluted EPS 0.11 0.07 0.11 0.06 0.05
Dividends Per Share 0.03 0.03 0.03 0.03 0.04
Total Assets 35,517.48M 37,200.39M 38,925.48M 45,114.51M 45,053.28M
Total liabilities 11,280.78M 13,307.23M 15,183.41M 18,765.36M 19,117.48M
Total equity 22,155.73M 21,985.74M 21,890.16M 21,994.00M 22,339.53M
Operating cash flow 1,863.97M 1,730.45M 2,006.03M 1,562.71M 2,683.04M
 Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019
Revenue 2,162.70M 2,419.15M 2,591.60M 2,854.98M 3,599.45M
Gross Profit 595.23M 641.58M 609.41M 719.20M 887.55M
Operating income 309.63M 296.36M 248.60M 307.46M 401.88M
Income before tax 307.76M 207.82M 270.34M 183.14M 233.79M
Net income 238.86M 147.81M 216.60M 134.27M 111.82M
EBITDA 485.98M 489.26M 476.09M 535.79M 729.05M
Diluted EPS 0.02 0.01 0.02 0.01 0.01
Dividends Per Share 0.00 0.00 0.00 0.00 0.00
Total Assets 8,272.38M 8,292.55M 9,618.35M 10,917.00M 11,014.12M
Total liabilities 2,627.40M 2,966.39M 3,751.77M 4,540.92M 4,673.63M
Total equity 5,160.29M 4,900.96M 5,408.98M 5,322.20M 5,461.32M
Operating cash flow 476.75M 417.70M 466.57M 387.25M 647.61M

Valuation Measures

Dec 2019
Operating margin11.16%
Profit margin3.10%

Key executives

  • Chief Executive Officer & Executive Director: Chi-Keon Loh
  • Group Chief Operating Officer: Suet Wun Lim
  • Group Chief Financial Officer: Soon Teck Low
  • Head-Strategic Planning & Business Development: Boon Kheng Chan
  • Group Head-Internal Audit: Audrey Huang


  • Mitsui & Co., Ltd. (32.9%)
  • Khazanah Nasional Bhd. (Investment Company) (26.0%)
  • Employees Provident Fund (7.9%)
  • Permodalan Nasional Bhd. (4.8%)
  • Public Mutual Bhd. (2.1%)
  • Kuwait Investment Authority (Investment Management) (1.6%)
  • Kumpulan Wang Persaraan (1.5%)
  • The Vanguard Group, Inc. (1.2%)
  • GIC Pte Ltd. (Investment Management) (1.0%)

Contact Details

  • Website:
  • Address: Level 11 Block A, Pantai Hospital, Kuala Lumpur, 8 Jalan Bukit Pantai, Kuala Lumpur, 59100, Malaysia
  • Phone: +60.3.2298.9898

Related Companies

  • Northern TK Venture Pte Ltd.
  • IHH Healthcare Bhd. (Singapore)
  • Centre For Digestive & Kidney Diseases India Pvt Ltd.
  • Acibadem Saglik Yatirimlari Holding AS
  • Indah Capital Ltd.
  • Shanghai Mai Kang Hospital Investment Management Co. Ltd.
  • Bodrum Tedavi Hizmetleri A.S
  • Integrated Healthcare Turkey Yatirimlari Ltd.
  • Gleneagles Development Pte Ltd.
  • Integrated Healthcare Holdings Ltd.
  • Acibadem Saglik Hizmetleri ve Ticaret AS
  • Pantai Holdings Sdn. Bhd.
  • Parkway Holdings Ltd.


    Last Updated on 9 Apr, 2020

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

    Stay ahead with our exclusives on Asia;
    the most dynamic market in the world.

    Stay ahead with our exclusives on Asia

    Get trusted insights from experts within Asia itself.

    Get trusted insights from experts
    within Asia itself.

    Get Unlimited access

    You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

    This is your last free article this month

    Stay ahead with our exclusives on Asia; the most
    dynamic market in the world

    Get trusted insights from experts
    within Asia itself.

    Try 3 months for $9

    Offer ends April 30th

    Your trial period has expired

    You need a subscription to...

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers and subscribe

    Your full access to the Nikkei Asian Review has expired

    You need a subscription to:

    • Read all stories with unlimited access
    • Use our mobile and tablet apps
    See all offers
    NAR on print phone, device, and tablet media